The third “Hansoh Blood Forum” was held in Shanghai on August 13rd 2017. Nearly 200 experts and doctors in blood disease prevention and control from all over the country attended the forum and jointly explored and discussed the latest domestic and international academic topics in blood-related fields.
The experts delivered excellent speeches on topics concerning the treatment and medication of such blood diseases as chronic myelogenous leukemia and myelodysplastic syndrome. Famous hematologists, including Professor Wang Jianxiang, Chairman of the Chinese Society of Hematology, Shen Zhixiang and Shao Zonghong, made observations and conclusions on the academic hot topics with an easy-to-understand approach that belied the profundity of their insights.
Launched in 2015, “Hansoh Blood Forum” is held annually, and this year marked the third consecutive session. The scale of the forum is expanding, and its influence increases every year. The forum, which aims to promote the progress and development of blood diagnosis and treatment in China, has become an important exchange and study platform for domestic doctors and scientific researchers in hematology and other related disciplines.
Committed to its corporate mission of “serving the society and promoting health”, Hansoh Pharma has made huge investments in research on neoplastic hematological disorders in recent years, with an effort to develop efficient, safe and affordable priority medicines for Chinese people. Hansoh Pharma’s hematologic tumor treatment products, Xinwei (Imatinib Mesylate Tablets) and Xinmei (Decitabine for Injection), launched in 2013 and 2014 respectively, provide Chinese people cutting edge medication at a cost as low as 1/3 of the original drugs. Due to the urgent demand of the public for Xinwei, the R&D project for it was included in the list of National Science and Technology Major Projects for “development of important new drugs” in the 12th Five-year Plan. Thanks to its huge social benefit, Xinwei has attracted broad attention from all walks of life. It was included in the NRDL this year, and will be gradually included in provincial reimbursement drug lists. The media have provided extensive reporting and publicity on this product. For instance, Jiangsu People’s Radio Station, Jiangsu finance and economics radio station, and Jiangsu traffic radio station jointly reported on the R&D, innovation and social benefits of Xinwei. (For details, please see the report at http://mp.weixin.qq.com/s/NDjZS4zXTlyV2p4qWMRyJA)
In the future, Hansoh Pharma will launch several other priority drugs in the hematologic tumor field, such as Flumatinib mesylate tablets, Xintai (Bortezomib for Injection), etc. With the successive offering of these new drugs, Hansoh Pharma has taken hematologic tumors as one of the key fields to conquer, and is committed to making greater contributions to the development of the anti-cancer cause in China.
